# Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

> **NCT02633059** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 33 (actual)

## Conditions studied

- Loss of Chromosome 17p
- Recurrent Plasma Cell Myeloma

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Idasanutlin
- **DRUG:** Ixazomib Citrate
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02633059
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-30
- **Primary completion:** 2021-01-31
- **Final completion:** 2022-11-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633059, "Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02633059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*